Systematic Review and Meta-Analysis to Identify the Immunocytochemical Markers Effective in Delineating Benign from Malignant Thyroid Lesions in FNAC Samples
Abstract Conventional cytology-based diagnosis for thyroid cancer is limited with more than 30–45% of nodules categorized as indeterminate, necessitating surgery for confirming or refuting the diagnosis. This systematic review and meta-analysis were aimed at identifying immunocytochemical markers effective in delineating benign from malignant thyroid lesions in fine needle aspiration cytology (FNAC) samples, thereby improving the accuracy of cytology diagnosis. A systematic review of relevant articles (2000–2021) from online databases was carried out and the search protocol registered in PROSPERO database (CRD42021229121). The quality of studies was assessed using QUADAS-2. Review Manager 5.4.1 from Cochrane collaboration and MetaDisc Version 1.4 was used to conduct the meta-analysis. Bias in the studies were visually analyzed using funnel plots, and statistical significance was evaluated by Egger’s test. Systematic review identified 64 original articles, while meta-analysis in eligible articles (n = 41) identified a panel of 5 markers, Galectin-3, HBME-1, CK-19, CD-56, and TPO. Assessment of the diagnostic performance revealed that Gal-3 (sensitivity: 0.81; CI: 0.79–0.83; specificity: 0.84; CI: 0.82–0.85) and HBME-1 (sensitivity: 0.83; Cl: 0.81–0.86; specificity: 0.85; CI: 0.83–0.86) showed high accuracy in delineating benign from malignant thyroid nodules. Efficacy analysis in indeterminate nodules showed Gal-3 and HBME-1 have high specificity of 0.86 (CI 0.84–0.89) and 0.82 (CI 0.78–0.86), respectively, and low sensitivity of 0.76 (CI 0.72–0.80) and 0.75 (CI 0.70–0.80), respectively. Diagnostic odds ratio (DOR) of Galectin-3 and HBME-1 were 39.18 (CI 23.38–65.65) and 24.44 (CI 11.16–53.54), respectively. Significant publication bias was observed for the markers Galectin-3 and CK-19 (p < 0.05). The panel of 5 markers identified from this meta-analysis are high-confidence candidates that need to be validated in thyroid cytology to establish their efficacy and enable clinical applicability..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Endocrine pathology - 33(2022), 2 vom: 21. Mai, Seite 243-256 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mohan, Uma [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Galectin-3 |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
---|
doi: |
10.1007/s12022-022-09721-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2078785512 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2078785512 | ||
003 | DE-627 | ||
005 | 20230510125913.0 | ||
007 | tu | ||
008 | 221220s2022 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s12022-022-09721-5 |2 doi | |
035 | |a (DE-627)OLC2078785512 | ||
035 | |a (DE-He213)s12022-022-09721-5-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Mohan, Uma |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systematic Review and Meta-Analysis to Identify the Immunocytochemical Markers Effective in Delineating Benign from Malignant Thyroid Lesions in FNAC Samples |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
520 | |a Abstract Conventional cytology-based diagnosis for thyroid cancer is limited with more than 30–45% of nodules categorized as indeterminate, necessitating surgery for confirming or refuting the diagnosis. This systematic review and meta-analysis were aimed at identifying immunocytochemical markers effective in delineating benign from malignant thyroid lesions in fine needle aspiration cytology (FNAC) samples, thereby improving the accuracy of cytology diagnosis. A systematic review of relevant articles (2000–2021) from online databases was carried out and the search protocol registered in PROSPERO database (CRD42021229121). The quality of studies was assessed using QUADAS-2. Review Manager 5.4.1 from Cochrane collaboration and MetaDisc Version 1.4 was used to conduct the meta-analysis. Bias in the studies were visually analyzed using funnel plots, and statistical significance was evaluated by Egger’s test. Systematic review identified 64 original articles, while meta-analysis in eligible articles (n = 41) identified a panel of 5 markers, Galectin-3, HBME-1, CK-19, CD-56, and TPO. Assessment of the diagnostic performance revealed that Gal-3 (sensitivity: 0.81; CI: 0.79–0.83; specificity: 0.84; CI: 0.82–0.85) and HBME-1 (sensitivity: 0.83; Cl: 0.81–0.86; specificity: 0.85; CI: 0.83–0.86) showed high accuracy in delineating benign from malignant thyroid nodules. Efficacy analysis in indeterminate nodules showed Gal-3 and HBME-1 have high specificity of 0.86 (CI 0.84–0.89) and 0.82 (CI 0.78–0.86), respectively, and low sensitivity of 0.76 (CI 0.72–0.80) and 0.75 (CI 0.70–0.80), respectively. Diagnostic odds ratio (DOR) of Galectin-3 and HBME-1 were 39.18 (CI 23.38–65.65) and 24.44 (CI 11.16–53.54), respectively. Significant publication bias was observed for the markers Galectin-3 and CK-19 (p < 0.05). The panel of 5 markers identified from this meta-analysis are high-confidence candidates that need to be validated in thyroid cytology to establish their efficacy and enable clinical applicability. | ||
650 | 4 | |a Thyroid | |
650 | 4 | |a Immunocytochemistry | |
650 | 4 | |a Systematic review | |
650 | 4 | |a Meta-analysis | |
650 | 4 | |a Galectin-3 | |
650 | 4 | |a HBME-1 | |
700 | 1 | |a Sunny, Sumsum P. |4 aut | |
700 | 1 | |a Mendonca, Pramila |4 aut | |
700 | 1 | |a Kuriakose, Moni A. |4 aut | |
700 | 1 | |a Kannan, Subramanian |4 aut | |
700 | 1 | |a Suresh, Amritha |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Endocrine pathology |d Springer US, 1990 |g 33(2022), 2 vom: 21. Mai, Seite 243-256 |w (DE-627)170267571 |w (DE-600)1033267-4 |w (DE-576)518175081 |x 1046-3976 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2022 |g number:2 |g day:21 |g month:05 |g pages:243-256 |
856 | 4 | 1 | |u https://doi.org/10.1007/s12022-022-09721-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
951 | |a AR | ||
952 | |d 33 |j 2022 |e 2 |b 21 |c 05 |h 243-256 |